'Pfizer And Partner BioNTech Say They Will Stop U.S. Covid-19 Vaccine Study In Healthy Adults Ages 50 To 64 Due To Slow Enrollment'

Pfizer and its partner BioNTech have announced the cessation of their U.S. Covid-19 vaccine study targeting healthy adults aged 50 to 64, citing slow enrollment as the primary reason. This decision may impact their ongoing vaccine development efforts and could affect their market position. The companies have not disclosed specific financial implications related to this study's termination.